title: Serum preadipocyte factor-1 concentrations in females with obesity and type 2 diabetes mellitus: the influence of very low calorie diet, acute hyperinsulinemia, and fenofibrate treatment.
abstract: Appropriate differentiation capacity of adipose tissue significantly affects its ability to store lipids and to protect nonadipose tissues against lipid spillover and development of insulin resistance. Preadipocyte factor-1 (Pref-1) is an important negative regulator of preadipocyte differentiation. The aim of our study was to explore the changes in circulating Pref-1 concentrations in female subjects with obesity (OB) (n=19), females with obesity and type 2 diabetes mellitus (T2DM) (n=22), and sex- and age-matched healthy control subjects (C) (n=22), and to study its modulation by very low calorie diet (VLCD), acute hyperinsulinemia during isoglycemic-hyperinsulinemic clamp, and 3 months' treatment with PPAR-α agonist fenofibrate. At baseline, serum Pref-1 concentrations were significantly higher in patients with T2DM compared to control group, while only nonsignificant trend towards higher levels was observed in OB group. 3 weeks of VLCD decreased Pref-1 levels in both OB and T2DM group, whereas 3 months of fenofibrate treatment had no significant effect. Hyperinsulinemia during the clamp significantly suppressed Pref-1 levels in both C and T2DM subjects and this suppression was unaffected by fenofibrate treatment. In a combined population of all groups, circulating Pref-1 levels correlated positively with insulin, leptin and glucose levels and HOMA (homeostasis model assessment) index. We conclude that elevated Pref-1 concentrations in T2DM subjects may contribute to impaired adipose tissue differentiation capacity associated with insulin resistance in obese patients with T2DM. The decrease of Pref-1 levels after VLCD may be involved in the improvement of metabolic status and the amelioration of insulin resistance in T2DM patients.
authors: Third Department of Medicine, General University Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic.
authors: P
authors: P
authors: Kavalkova
authors: V
authors: V
authors: Touskova
authors: T
authors: T
authors: Roubicek
authors: P
authors: P
authors: Trachta
authors: M
authors: M
authors: Urbanova
authors: J
authors: J
authors: Drapalova
authors: D
authors: D
authors: Haluzikova
authors: M
authors: M
authors: Mraz
authors: D
authors: D
authors: Novak
authors: M
authors: M
authors: Matoulek
authors: Z
authors: Z
authors: Lacinova
authors: M
authors: M
authors: Haluzik
mesh_terms: D000886:Anthropometry; D001835:Body Weight; D002135:Calcium-Binding Proteins; D031204:Caloric Restriction; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D015309:Glucose Clamp Technique; D006801:Humans; D006946:Hyperinsulinism / Q000097:blood* / Q000188:drug therapy; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000178:diet therapy* / Q000188:drug therapy; D047493:PPAR alpha / Q000819:agonists / Q000378:metabolism
chemical_list: D002135:Calcium-Binding Proteins; C512941:DLK1 protein, human; D036341:Intercellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D047493:PPAR alpha; D011345:Fenofibrate